Cingulate Inc.

CING | NASDAQ

Price Alert Chart Builder DCF Calculator

$5.23

-$0.01 (-0.19%)

At close: Sep 21, 2026, 4:00 PM ET

$5.27

+$0.04 (+0.75%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.19%

(1D)

Rating

Updated: Aug 29, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $70.44M

1D Range

5.22 5.43

52W Range

3.16 11.89

Valuation (TTM)

PE -1.19

PB 0.00

EV/EBITDA 1,117.61

Valuation (NTM)

Forward PE N/A

Forward PEG 0.06

Price Target $9

Cash Flow

FCF Yield -18381.8%

SBC Adj. FCF Yield -19739.4%

SBC Impact -7.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 130.1% | 72.9%

FCF 3Y | 5Y -149.4% | -99.4%

Returns

ROA -87.1%

ROE -238.4%

ROIC -83.7%

Financial Health

Net Cash

$27.18B

Current Ratio 3.50

Interest Coverage 20.43

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its...

Sector Healthcare

Industry Biotechnology

Employees 14

IPO Date Dec 7, 2021

Website www.cingulate.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+72.08%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞